EKTA.B

48.46

+0.04%↑

EKTA.B

48.46

+0.04%↑

EKTA.B

48.46

+0.04%↑

EKTA.B

48.46

+0.04%↑

EKTA.B

48.46

+0.04%↑

Search

Vivesto AB

Fermé

0.22

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.22

Max

0.22

Chiffres clés

By Trading Economics

Revenu

2.4M

-8.3M

BPA

-0.015

Employés

4

Dividendes

By Dow Jones

Prochains Résultats

12 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-1.1M

123M

Ouverture précédente

0.22

Clôture précédente

0.22

Vivesto AB Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

9 juil. 2025, 15:46 UTC

Principaux Mouvements du Marché

BitMine Shares Fall After Closing of $250 Million Private Placement

9 juil. 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9 juil. 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 juil. 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9 juil. 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9 juil. 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9 juil. 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

9 juil. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juil. 2025, 20:26 UTC

Résultats

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9 juil. 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9 juil. 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9 juil. 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9 juil. 2025, 17:07 UTC

Market Talk
Acquisitions, Fusions, Rachats

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9 juil. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9 juil. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 juil. 2025, 16:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

9 juil. 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 juil. 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9 juil. 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9 juil. 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9 juil. 2025, 16:14 UTC

Acquisitions, Fusions, Rachats

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9 juil. 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9 juil. 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9 juil. 2025, 15:31 UTC

Principaux Mouvements du Marché

BitMine Shares Fall After Closing of $250M Private Placement

9 juil. 2025, 15:31 UTC

Market Talk
Acquisitions, Fusions, Rachats

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9 juil. 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9 juil. 2025, 14:36 UTC

Acquisitions, Fusions, Rachats

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9 juil. 2025, 14:31 UTC

Acquisitions, Fusions, Rachats

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9 juil. 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9 juil. 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Comparaison

Variation de prix

Vivesto AB prévision

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.